Tetrabenazine, the first selective VMAT2 inhibitor, was approved in 2008 by the Food and Drug Administration (FDA) to treat chorea associated with Huntington’s disease (HD) after showing benefits in a randomized controlled trial (RCT) [7]. This evidence concerns the gene SLC18A2 and Chorea.